Savara (SVRA) Tax Provisions (2017 - 2018)
Savara's (SVRA) quarterly Tax Provisions came in at $2.5 million in Q4 2018, up 188.97% year-on-year from $865147.8 in Q4 2017, and up 2372.73% on a QoQ basis from -$110000.0 in Q3 2018.
Savara (SVRA) Tax Provisions (2017 - 2018) Analysis & Trends
Savara (SVRA) has 2 years of Tax Provisions data on file, last reported at $2.5 million in Q4 2018.
- On a quarterly basis, Tax Provisions rose 188.97% year-over-year to $2.5 million in Q4 2018; TTM through Dec 2018 was -$2.4 million, a 32.8% increase from a year earlier, with the FY2019 full-year figure at -$16.4 million, down 13338.71% from the prior year.
- Tax Provisions for Q4 2018 stood at $2.5 million, up from -$110000.0 in the prior quarter.
- Over the last five years, Tax Provisions for SVRA reached as high as $2.5 million in Q4 2018 and fell as low as -$4.6 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 31.86 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -60.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 2.50 Mn |
| Sep 30, 2018 | -110,000.00 |
| Jun 30, 2018 | -277,000.00 |
| Mar 31, 2018 | -4.56 Mn |
| Dec 31, 2017 | -2.81 Mn |
| Sep 30, 2017 | -117,000.00 |
| Jun 30, 2017 | -470,000.00 |
| Mar 31, 2017 | -237,000.00 |